Abstract
This is a review of the effect of duloxetine on pain in pre-clinical studies as well as in clinical studies in patients with diabetic peripheral neuropathic pain (DPNP) and fibromyalgia (FM), and painful symptoms associated with major depressive disorder (MDD) and generalized anxiety disorder (GAD). Data sources include the pre-clinical studies of duloxetine in rodent pain models, and randomized, double-blind, placebo-controlled trials of the efficacy of duloxetine (20-120 mg/day) in the management of chronic pain in DPNP and FM, and in MDD and GAD trials that included pain measures. In pre-clinical studies, duloxetine reduced pain in animal models of central and neuropathic chronic pain states. In the clinical trials, duloxetine (60-120 mg/day) significantly reduced the severity of pain in patients with DPNP and FM. In pooled analyses of the MDD and GAD studies, there was a significant main effect of treatment with duloxetine on painful symptoms. The results from these studies demonstrate that duloxetine reduces pain in pre-clinical animal studies, clinical studies of patients with FM and DPNP, and in painful symptoms associated with MDD and GAD.
Keywords: Anxiety, depression, diabetic neuropathic pain, duloxetine, fibromyalgia, pain, Chronic pain, Neuropathic Pain, generalized anxiety disorder, diabetic peripheral neuropathic pain, major depressive disorder
Current Drug Therapy
Title: Management of Painful Symptoms with Duloxetine: A Review of the Efficacy in Pre-Clinical and Clinical Studies
Volume: 6 Issue: 2
Author(s): Michael J. Robinson, Jonna Ahl, Adam L. Meyers, Bill H. McCarberg and Smriti Iyengar
Affiliation:
Keywords: Anxiety, depression, diabetic neuropathic pain, duloxetine, fibromyalgia, pain, Chronic pain, Neuropathic Pain, generalized anxiety disorder, diabetic peripheral neuropathic pain, major depressive disorder
Abstract: This is a review of the effect of duloxetine on pain in pre-clinical studies as well as in clinical studies in patients with diabetic peripheral neuropathic pain (DPNP) and fibromyalgia (FM), and painful symptoms associated with major depressive disorder (MDD) and generalized anxiety disorder (GAD). Data sources include the pre-clinical studies of duloxetine in rodent pain models, and randomized, double-blind, placebo-controlled trials of the efficacy of duloxetine (20-120 mg/day) in the management of chronic pain in DPNP and FM, and in MDD and GAD trials that included pain measures. In pre-clinical studies, duloxetine reduced pain in animal models of central and neuropathic chronic pain states. In the clinical trials, duloxetine (60-120 mg/day) significantly reduced the severity of pain in patients with DPNP and FM. In pooled analyses of the MDD and GAD studies, there was a significant main effect of treatment with duloxetine on painful symptoms. The results from these studies demonstrate that duloxetine reduces pain in pre-clinical animal studies, clinical studies of patients with FM and DPNP, and in painful symptoms associated with MDD and GAD.
Export Options
About this article
Cite this article as:
J. Robinson Michael, Ahl Jonna, L. Meyers Adam, H. McCarberg Bill and Iyengar Smriti, Management of Painful Symptoms with Duloxetine: A Review of the Efficacy in Pre-Clinical and Clinical Studies, Current Drug Therapy 2011; 6 (2) . https://dx.doi.org/10.2174/157488511795304903
DOI https://dx.doi.org/10.2174/157488511795304903 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Modern Treatment of Infection and Ischaemia to Reduce Major Amputation in the Diabetic Foot
Current Pharmaceutical Design Diuretic-Associated Electrolyte Disorders in the Elderly: Risk Factors, Impact, Management and Prevention
Current Drug Safety Effects of Antioxidant Polyphenols on TNF-Alpha-Related Diseases
Current Topics in Medicinal Chemistry Lipoic Acid as a Potential Therapy for Chronic Diseases Associated with Oxidative Stress
Current Medicinal Chemistry Drugs Treatment of Pain in Multiple Sclerosis
Current Clinical Pharmacology Anti-Hyperglycemic and Hypolipidemic Effects of Different Aloe vera (Aloe Barbadensis Miller) Extracts in the Management of Obesity and Diabetes
Current Nutrition & Food Science The Role of H. pylori Infection in Diabetes
Current Diabetes Reviews Adiposity and Alzheimers Disease
Current Alzheimer Research The Impact of Substance P on the Pathogenesis of Insulin Resistance Leading to Gestational Diabetes
Current Pharmaceutical Biotechnology Common Genetic Variants of the Mitochondrial Trafficking System and Mitochondrial Uncoupling Proteins Affect the Development of Two Slowly Developing Demyelinating Disorders, Leukoaraiosis and Multiple Sclerosis
Current Medicinal Chemistry Clinical Trials of Cancer Therapies Targeting Prostate-Specific Membrane Antigen
Reviews on Recent Clinical Trials Cognitive Impairment and Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Biological Basis of Novel Therapies for Myelodysplastic Syndrome
Current Cancer Therapy Reviews Rhodanine as a Privileged Scaffold in Drug Discovery
Current Medicinal Chemistry Novel Mitotic Targets and Their Small-Molecule Inhibitors
Current Cancer Drug Targets Endocannabinoids as Regulators of Transient Receptor Potential (TRP)Channels: a Further Opportunity to Develop New Endocannabinoid-Based Therapeutic Drugs
Current Medicinal Chemistry Antioxidant and Antiinflammatory Activities of Curcumin on Diabetes Mellitus and its Complications
Current Pharmaceutical Design The ERK 1 and 2 Pathway in the Nervous System: From Basic Aspects to Possible Clinical Applications in Pain and Visceral Dysfunction
Current Neuropharmacology Meet Our Editorial Board Member:
Applied Clinical Research, Clinical Trials and Regulatory Affairs Mitochondrial Diseases in Childhood
Current Molecular Medicine